Lisata Therapeutics, Inc. (NASDAQ:LSTA) Short Interest Up 50.2% in February

Lisata Therapeutics, Inc. (NASDAQ:LSTA) saw a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 40,100 shares, an increase of 50.2% from the February 13th total of 26,700 shares. Currently, 0.6% of the shares of the company are sold short. Based on an average daily trading volume, of 41,400 shares, the short-interest ratio is presently 1.0 days.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Lisata Therapeutics in a report on Wednesday, December 11th.

Lisata Therapeutics Trading Up 3.0 %

NASDAQ:LSTA traded up $0.07 during midday trading on Friday, hitting $2.39. 1,708 shares of the stock were exchanged, compared to its average volume of 21,797. Lisata Therapeutics has a one year low of $2.05 and a one year high of $4.20. The company has a market capitalization of $20.60 million, a price-to-earnings ratio of -0.95 and a beta of 1.16. The business has a 50-day moving average price of $2.78 and a two-hundred day moving average price of $2.87.

Lisata Therapeutics (NASDAQ:LSTA) last announced its earnings results on Thursday, February 27th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.21. The firm had revenue of $1.00 million for the quarter. Sell-side analysts forecast that Lisata Therapeutics will post -2.66 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Lisata Therapeutics stock. Dimensional Fund Advisors LP boosted its position in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 45.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 25,226 shares of the company’s stock after purchasing an additional 7,886 shares during the period. Dimensional Fund Advisors LP owned 0.30% of Lisata Therapeutics worth $75,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.